Pure Global AI
NCT06305078Recruiting

Personalized Attention-Deficit/Hyperactivity Disorder (ADHD) Medication Experiment Study

Open-Label Trial of Personalized Medication Experiments to Inform Decisions About Future Attention-Deficit/Hyperactivity Disorder (ADHD) Medication Use
Children's Hospital Medical Center, CincinnatiClinicalTrials.govother
Verified
Study focus
Disease/Condition
Attention Deficit Hyperactivity Disorder
Drug/Device/Intervention
Personalized ADHD Medication Experiment
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Children's Hospital Medical Center, Cincinnati
Location
Cincinnati, United States of America
Timeline & enrollment
Phase
N/A
Start date
Nov 10, 2023
End date
Dec 31, 2024
Enrollment
30 participants
Primary outcome

Decision-Making Involvement Scale,Decisional Conflict Scale (DCS),Behavioral Intention Questions,System Usability Scale,Implementation of Decision

Summary

The primary goal of the project is to test personalized medication experiments to inform
 decisions about future medication use. Our central hypothesis is that our intervention will
 lead to within subject increases in adolescent involvement in decision making and decreases
 in uncertainty about future medication use. The investigators view this open label trial as a
 pilot study to test the feasibility, acceptability, and preliminary efficacy of the
 medication experiment intervention and therefore warrants further testing in a future larger
 trial.

ICD-10 classifications
Neurotic disorder, unspecifiedHyperkinetic disorder, unspecifiedHabit and impulse disorder, unspecifiedMild cognitive disorderDisturbance of activity and attention
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06305078
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06305078 through Pure Global AI's free database. This phase not specified trial is sponsored by Children's Hospital Medical Center, Cincinnati and is currently Recruiting. The study focuses on Attention Deficit Hyperactivity Disorder. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.